We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.58B
AUM Growth
+$403M
Cap. Flow
+$220M
Cap. Flow %
13.93%
Top 10 Hldgs %
32.67%
Holding
149
New
11
Increased
79
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.7M
3
PACB icon
Pacific Biosciences
PACB
+$11M
4
MDT icon
Medtronic
MDT
+$8.74M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$8.4M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.7M
2
BHC icon
Bausch Health
BHC
+$3.02M
3
AMGN icon
Amgen
AMGN
+$2.16M
4
GILD icon
Gilead Sciences
GILD
+$1.72M
5
KTWO
K2M Group Holdings, Inc
KTWO
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 93.18%
2 Industrials 1.09%
3 Technology 0.34%
4 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
1
Elevance Health
ELV
$80.9B
$61.4M 3.9%
224,188
+10,661
+5% +$2.77M
ALGN icon
2
Align Technology
ALGN
$12.7B
$57.2M 3.63%
146,310
+15,252
+12% +$5.63M
ABT icon
3
Abbott
ABT
$175B
$56.2M 3.57%
766,710
+197,860
+35% +$13M
CELG
4
DELISTED
Celgene Corp
CELG
$54.2M 3.44%
606,000
+73,200
+14% +$6.47M
ILMN icon
5
Illumina
ILMN
$28.2B
$54.2M 3.44%
151,843
+6,925
+5% +$2.22M
TDOC icon
6
Teladoc Health
TDOC
$1.7B
$50.6M 3.21%
586,520
+16,410
+3% +$1.17M
ISRG icon
7
Intuitive Surgical
ISRG
$122B
$50.4M 3.2%
263,604
+387
+0.1% +$68.7K
MDT icon
8
Medtronic
MDT
$106B
$48.8M 3.1%
496,446
+94,565
+24% +$8.74M
EW icon
9
Edwards Lifesciences
EW
$49.4B
$44.1M 2.8%
759,999
+143,019
+23% +$6.99M
BSX icon
10
Boston Scientific
BSX
$65.4B
$37.7M 2.39%
978,929
+158,333
+19% +$5.53M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.5B
$35.9M 2.28%
213,758
+48,825
+30% +$8.4M
CI icon
12
Cigna
CI
$74.5B
$35.3M 2.24%
169,463
+43,229
+34% +$8.01M
HUM icon
13
Humana
HUM
$48B
$33.3M 2.12%
98,510
+11,660
+13% +$3.79M
UNH icon
14
UnitedHealth
UNH
$387B
$32.9M 2.09%
123,848
+27,119
+28% +$7.05M
CNC icon
15
Centene
CNC
$32.8B
$31.6M 2%
436,042
+109,548
+34% +$7.61M
BDX icon
16
Becton Dickinson
BDX
$43.6B
$27.5M 1.75%
108,048
+24,803
+30% +$6.11M
DHR icon
17
Danaher
DHR
$144B
$27.5M 1.74%
285,402
+38,973
+16% +$3.55M
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
$25.4M 1.61%
183,080
+19,350
+12% +$2.43M
SYK icon
19
Stryker
SYK
$123B
$25.1M 1.59%
141,380
+22,610
+19% +$3.86M
COR icon
20
Cencora
COR
$59.9B
$22M 1.4%
238,853
– –
BMY icon
21
Bristol-Myers Squibb
BMY
$124B
$21.2M 1.35%
341,729
+80,880
+31% +$4.8M
VTRS icon
22
Viatris
VTRS
$20.1B
$20.7M 1.31%
565,350
+63,000
+13% +$2.36M
BAX icon
23
Baxter International
BAX
$11.7B
$20.3M 1.29%
263,348
+53,348
+25% +$3.96M
SUPN icon
24
Supernus Pharmaceuticals
SUPN
$2.79B
$19.5M 1.23%
386,500
+59,900
+18% +$2.96M
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$35.7B
$19.2M 1.22%
219,891
+116,391
+112% +$11.7M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2018 Portfolio in Review

As of Q3 2018, Bellevue Group held 149 positions worth $1.58B, up 34% from $1.17B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $220M of net new capital in Q3 2018, opening 11 new positions and adding to 79 existing holdings. Its largest new stake was Pacific Biosciences: 2,575,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was DexCom, an estimated $24.7M trimmed.

  • Bellevue Group's largest Q3 2018 buy was Pacific Biosciences: 2,575,000 shares worth $13.9M.
  • Bellevue Group added most to Abbott in Q3 2018, an estimated $13M increase.
  • Bellevue Group's biggest Q3 2018 reduction was DexCom, cutting an estimated $24.7M.
  • Bellevue Group fully exited Bausch Health in Q3 2018, selling an estimated $3.02M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.58B portfolio in Q3 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q3 2018.
  • Bellevue Group's portfolio value rose 34% quarter-over-quarter to $1.58B.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.